Get the Stockscreener App
1.05
5.41%
-0.06
After Hours:
1.10
0.05
+4.76%
Immunic Inc stock is traded at $1.05, with a volume of 844.01K.
It is down -5.41% in the last 24 hours and down -9.48% over the past month.
See More
Previous Close:
$1.11
Open:
$1.07
24h Volume:
844.01K
Relative Volume:
0.98
Market Cap:
$94.58M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.4976
EPS:
-2.11
Net Cash Flow:
$-71.16M
1W Performance:
-15.32%
1M Performance:
-9.48%
6M Performance:
-33.96%
1Y Performance:
-13.93%
1-Day Range:
$1.03
$1.09
1-Week Range:
$1.02
$1.28
52-Week Range:
$0.9204
$2.11
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
1.05 | 94.58M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Immunic (NASDAQ:IMUX) Given “Buy” Rating at D. Boral Capital - Defense World
Immunic to present at AAN 2025 and German Biotech Days in April - Proactive Investors
Immunic, Inc. to Participate in Scientific and Industry Conferences in April - The Victoria Advocate
IMMUNIC, INC. SEC 10-K Report - TradingView
Immunic CMO discusses significance of MS Awareness Month; progress with treatment - Proactive Investors
Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average PT from Brokerages - Defense World
180 Life Sciences (NASDAQ:ATNF) versus Immunic (NASDAQ:IMUX) Head to Head Comparison - Defense World
Immunic (NASDAQ:IMUX) Now Covered by Analysts at William Blair - Defense World
Immunic (NASDAQ:IMUX) Now Covered by William Blair - The AM Reporter
William Blair Initiates Coverage of Immunic (IMUX) with Outperform Recommendation - Nasdaq
William Blair sees Immunic stock outperforming on RMS therapy By Investing.com - Investing.com Australia
How did Immunic Inc (IMUX) fare last session? - uspostnews.com
William Blair sees Immunic stock outperforming on RMS therapy - Investing.com
Companies Like Immunic (NASDAQ:IMUX) Could Be Quite Risky - Yahoo Finance
William Blair Initiates Immunic at Outperform With $6.80 Price Target - MarketScreener
Buy Rating on Immunic Driven by Promising CALLIPER Study Outcomes and Market Opportunities in Progressive Multiple Sclerosis - TipRanks
Immunic’s Vidofludimus Calcium: A Promising Disruptor in the $45 Billion Multiple Sclerosis Market - TipRanks
StockNews.com Downgrades Immunic (NASDAQ:IMUX) to Sell - Defense World
Immunic provides MS research update – ICYMI - Proactive Investors Australia
Immunic (NASDAQ:IMUX) Raised to “Hold” at StockNews.com - Defense World
Immunic at Leerink’s Conference: Strategic Moves in MS Treatment - Investing.com India
Immunic at Leerink’s Conference: Strategic Moves in MS Treatment By Investing.com - Investing.com South Africa
Immunic Therapeutics advances MS Drug , Phase 2 CALLIPER trial readout in April - Proactive financial news
Immunic (IMUX) to Release Quarterly Earnings on Thursday - Defense World
Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average PT from Analysts - Defense World
Immunic presents at ACTRIMS forum as it awaits key CALLIPER MS trial data - Proactive Investors
Immunic to Participate in Scientific and Investor Conferences in March - Kilgore News Herald
Immunic announces participation in Hamburg and Miami conferences - Proactive Investors USA
Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for Immunic (NASDAQ:IMUX) - MarketBeat
Biotechs challenge big pharma with new oral weight loss therapies - Proactive Investors USA
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis - The Malaysian Reserve
Immunic to highlight vidofludimus calcium’s potential as MS therapy at upcoming forum - Proactive Investors
Immunic to highlight vidofludimus calcium’s potential as MS therapy at upcoming forum | NASDAQ:IMUX - Proactive financial news
Immunic (NASDAQ:IMUX) Receives Buy Rating from HC Wainwright - MarketBeat
How Do Things Look For Immunic Inc (NASDAQ: IMUX) In The Short-Term? - Stocks Register
Immunic's (IMUX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Immunic (NASDAQ:IMUX) Earns Buy Rating from HC Wainwright - Defense World
Immunic (IMUX) to Release Earnings on Thursday - MarketBeat
Immunic drug candidate may offer new obesity treatmentICYMI - Proactive financial news
Immunic, Inc.'s (NASDAQ:IMUX) largest shareholders are retail investors who were rewarded as market cap surged US$24m last week - Yahoo Finance
H.C. Wainwright maintains Immunic stock Buy rating, $10 target By Investing.com - Investing.com Nigeria
H.C. Wainwright maintains Immunic stock Buy rating, $10 target - Investing.com
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing - The Malaysian Reserve
Market movers: Walmart, Palantir, Immunic, Alibaba… - Proactive Investors UK
Immunic’s IMU-856 shows promise in weight management By Investing.com - Investing.com Nigeria
Immunic highlights IMU-856’s potential as weight management therapy - Proactive Investors Australia
Immunic's IMU-856 shows promise in weight management - Investing.com
Immunic’s IMU-856 shows promise for obesity treatment - Proactive Investors USA
Immunic's IMU-856 shows promise in weight management By Investing.com - Investing.com South Africa
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):